Company: IMCR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001671927-25-000014
Chunk: 16

Company: Immunocore Holdings plc
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
umulated deficit(801,038)(795,761)Accumulated other comprehensive loss(26,614)(33,763)Total shareholders' equity388,481 360,716 Total liabilities and shareholders' equity$1,082,387 $1,009,506 

The accompanying notes form an integral part of these condensed consolidated financial statements.

2

Table of Contents

 Immunocore Holdings plc

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited) (In thousands, except share and per share data)

Three Months Ended June 30,Six Months Ended June 30,2025202420252024Revenue:Revenue from sale of therapies, net$97,964 $75,347 $191,845 $145,689 Collaboration revenue— 53 — 213 Total revenue97,964 75,400 191,845 145,902 Cost and operating expenses:Cost of revenue from sale of therapies(1,040)(1,707)(1,871)(1,953)Research and development expense(69,008)(51,072)(125,476)(108,531)Selling, general and administrative expense(42,791)(38,638)(82,989)(77,925)Loss from operations(14,875)(16,017)(18,491)(42,507)Other income (expense):Interest income4,271 6,239 8,447 14,485 Interest expense(3,045)(4,277)(6,070)(7,516)Foreign currency (loss) gain(738)(508)2,342 (2,914)Other income, net4,693 4,433 10,162 4,243 Net loss before income taxes(9,694)(10,130)(3,610)(34,209)Income tax expense(606)(1,486)(1,667)(1,843)Net loss$(10,300)$(11,616)$(5,277)$(36,052)Other comprehensive income:Exchange differences on translation of foreign operations6,476 944 7,149 1,841 Total comprehensive (loss) income$(3,824)$(10,672)$1,872 $(34,211)Basic and diluted net loss per share$(0.20)$(0.23)$(0.11)$(0.72)Basic and diluted weighted